Previous 10 | Next 10 |
Roche's ( OTCQX:RHHBY ) $4.3B takeover of Spark Therapeutics (NASDAQ: ONCE ) has been pushed back again, possibly beyond the first half of 2019, as regulators continue to scrutinize the deal for its effect on competition. More news on: Roche Holding AG, Spark Therapeutics, Inc., Roche Ho...
In the world of securities, courage becomes the supreme virtue after adequate knowledge and a tested judgment are at hand. - Benjamin Graham (The Father of Value Investing) Though there are different approaches to a successful investment, I leverage on one that is tailored specifically for...
SPDR Biotech ETF (NYSE: XBI ) provides investors diversified exposure to one of the most exciting industries in the market. Diversified is a relative term here because biotechnology companies, particularly those that are still in early stages of drug development, are often times the riskie...
This article explains the reasons behind the movement in a selection of the largest U.S. cash merger arbitrage spreads from the past week as calculated by Merger Arbitrage Limited . We analyze the attractiveness and profitability of each spread going forward and indicate the trading position ...
I've taken the M&A dashboard as a base to quickly review the most interesting M&A deals that are ongoing. I've highlighted the deals that I think are interesting and where I had/have/consider a position and briefly discuss them below. Here's are the first few rows of the dashboard with...
This article is part of a series that provides an ongoing analysis of the changes made to Prem Watsa’s 13F portfolio on a quarterly basis. It is based on Watsa’s regulatory 13F Form filed on 05/15/2019. Please visit our Tracking Prem Watsa’s Fairfax Financial Holdings P...
Biotech Pulse The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have struggled since March as the broader healthcare sector ( XLV ) declined following growing momentum amongst the presidential candidates for a universal healthcare plan. This was at a time when the broader ma...
This article explains the reasons behind the movement in a selection of the largest U.S. cash merger arbitrage spreads from the past week as calculated by Merger Arbitrage Limited . We analyze the attractiveness and profitability of each spread going forward and indicate the trading positio...
After a very active prior week where we saw nine new deals announced, merger activity decreased last week with two new deals announced and four pending deals closing. Deal Statistics: New Deals: The acquisition of Amber Road (AMBR) by E2open for $425 million or $13.05 per share ...
Each quarter, I spend some time reading Form 13F filings from the hedge funds that specialize in merger arb, documenting, and analyzing which M&A stocks the funds have bought and which ones they haven't. I then compile the top 10 stocks held in these funds and share the results with the ...
News, Short Squeeze, Breakout and More Instantly...
Spark Therapeutics Inc. Company Name:
ONCE Stock Symbol:
NASDAQ Market:
Spark Therapeutics Inc. Website:
Genetics is the study of genes, their variations and hereditary characteristics. As Live Science describes it , genetics involves looking at how traits are passed on through generations. So, what is genetics investing? When it comes to genetics investing, companies in this niche...
After big biopharma Astellas (OTC: ALPMY) (OTC: ALPMF) agreed to acquire clinical-stage gene therapy company Audentes Therapeutics (NASDAQ: BOLD) for $3 billion in cash, uniQure 's (NASDAQ: QURE) shares have jumped 13% at 12:15 pm EDT on Tuesday. Although Audentes and uni...
PHILADELPHIA, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that the Galien Foundation has awarded the prestigious 2019 Prix Galien USA Aw...